NASDAQ:CSBR Champions Oncology (CSBR) Stock Price, News & Analysis → Central Banks Preparing for US Dollar Collapse? (From Behind the Markets) (Ad) Free CSBR Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$4.90▼$5.0250-Day Range$9.11▼$10.9652-Week Range$7.19▼$14.68Volume3,382 shsAverage Volume5,655 shsMarket Capitalization$66.59 millionP/E RatioN/ADividend YieldN/APrice Target$7.50 Stock AnalysisStock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipShort InterestSocial MediaSustainability Get Champions Oncology alerts: Email Address Champions Oncology MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside53.1% Upside$7.50 Price TargetShort InterestHealthy1.03% of Float Sold ShortDividend StrengthN/ASustainability-0.92Upright™ Environmental ScoreNews Sentiment1.04Based on 14 Articles This WeekInsider TradingAcquiring Shares$46,322 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.04 out of 5 starsMedical Sector242nd out of 938 stocksBiological Products, Except Diagnostic Industry31st out of 155 stocks 3.3 Analyst's Opinion Consensus RatingChampions Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.50, Champions Oncology has a forecasted upside of 53.1% from its current price of $4.90.Amount of Analyst CoverageChampions Oncology has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.03% of the float of Champions Oncology has been sold short.Short Interest Ratio / Days to CoverChampions Oncology has a short interest ratio ("days to cover") of 6.Change versus previous monthShort interest in Champions Oncology has recently decreased by 2.95%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldChampions Oncology does not currently pay a dividend.Dividend GrowthChampions Oncology does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreChampions Oncology has received a 68.94% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer", "Preclinical research services for physical health", and "Basic medical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Champions Oncology is -0.92. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 14 news articles for Champions Oncology this week, compared to 9 articles on an average week. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Champions Oncology insiders have bought more of their company's stock than they have sold. Specifically, they have bought $46,322.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders45.69% of the stock of Champions Oncology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions41.30% of the stock of Champions Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Champions Oncology is -6.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Champions Oncology is -6.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Vertical Research Advisory“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!Click here for all the details now… About Champions Oncology Stock (NASDAQ:CSBR)Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.Read More Ad Vertical Research Advisory“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!Click here for all the details now… CSBR Stock News HeadlinesMarch 29, 2024 | msn.comBarcelona 3-1 Brann (agg 5-2): Barca set up Champions League semi-final against ChelseaMarch 29, 2024 | msn.comNapoli relaunch Champions League push as Jesus racism storm rumbles onMarch 29, 2024 | Vertical Research Advisory (Ad)“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!March 29, 2024 | reuters.comPSG, Barcelona ease into women's Champions League semisMarch 29, 2024 | barrons.comFootball: Women's Champions League ResultsMarch 29, 2024 | msn.comMasters Champions Dinner excites Dustin Johnson. But there's 1 thingMarch 29, 2024 | barrons.comBarcelona Down Brann To Set Up Chelsea Champions League RematchMarch 29, 2024 | msn.comBarcelona wins to set up Women's Champions League semifinal vs. Chelsea. PSG advances to face LyonMarch 29, 2024 | Vertical Research Advisory (Ad)“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!March 28, 2024 | msn.comChelsea and Lyon progress into this year’s Women’s Champions League semifinalsMarch 28, 2024 | msn.comTiger Woods' old Masters rival urges LIV Golf to buy PGA's Champions TourMarch 28, 2024 | msn.comFrance include nine Champions League players in squad for Euro 2025 qualifying clash with IrelandMarch 28, 2024 | msn.com'Tournament of Champions' quarterfinals battle: OKC's Kevin Lee to face Antonia LofasoMarch 28, 2024 | msn.comUEFA Champions league power rankings for the quarterfinalsMarch 28, 2024 | msn.comThe Masters: Ranking Top 5 Champions Dinner Menu of All TimeMarch 19, 2024 | finance.yahoo.comChampions Oncology, Inc. (NASDAQ:CSBR) Q3 2024 Earnings Call TranscriptMarch 18, 2024 | msn.comBarcelona and Lyon headline Women’s Champions League quarterfinals. Hayes’ Chelsea targets quadrupleMarch 18, 2024 | msn.comPark Place defeats La Irenita in the Founders Cup at Grand Champions Polo ClubMarch 18, 2024 | bbc.co.ukWomen's Champions League: Chelsea midfielder Erin Cuthbert says 'it's hard not to dream a little bit'March 18, 2024 | msn.com‘Champions,' ‘The Witcher: Blood Origin,' ‘All the Light We Cannot See' Among Ruderman Family Foundation Awardees for InclusionMarch 18, 2024 | msn.comBellator Champions Series: Belfast – Make your predictions for two title fightsMarch 18, 2024 | ca.news.yahoo.comBarcelona and Lyon headline Women's Champions League quarterfinals. Hayes' Chelsea targets quadrupleMarch 18, 2024 | msn.comChampions League returns with history makers & quadruple chasersMarch 18, 2024 | msn.com'Tournament of Champions': What happened when OKC's Kevin Lee took on Shirley Chung?March 17, 2024 | msn.comManchester United: Erik ten Hag sends Champions League warning to Tottenham after FA Cup winMarch 17, 2024 | msn.comAchraf Hakimi: "I came to PSG to win the Champions League"March 17, 2024 | forbes.comFC Barcelona Champions League Tie ‘Like Christmas’ Says PSG Coach Luis EnriqueSee More Headlines Receive CSBR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Champions Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings12/12/2023Today3/28/2024Fiscal Year End4/30/2024Next Earnings (Estimated)7/22/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:CSBR CUSIPN/A CIK771856 Webwww.championsoncology.com Phone(201) 808-8400Fax410-369-0390Employees143Year FoundedN/APrice Target and Rating Average Stock Price Target$7.50 High Stock Price Target$7.50 Low Stock Price Target$7.50 Potential Upside/Downside+53.1%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,340,000.00 Net Margins-19.76% Pretax Margin-19.62% Return on Equity-850.72% Return on Assets-32.62% Debt Debt-to-Equity RatioN/A Current Ratio0.60 Quick Ratio0.60 Sales & Book Value Annual Sales$53.87 million Price / Sales1.24 Cash FlowN/A Price / Cash FlowN/A Book Value($0.15) per share Price / Book-32.67Miscellaneous Outstanding Shares13,590,000Free Float7,383,000Market Cap$66.59 million OptionableOptionable Beta0.40 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesRonnie MorrisPresident Chief Executive Officer & DirectorDavid Barry MillerChief Financial OfficerKarin Abarca HeidemannVice President-Scientific OperationsMichael RitchieChief Commercial OfficerMaria ManciniVice President-PharmacologyKey CompetitorsAtara BiotherapeuticsNASDAQ:ATRAGenenta ScienceNASDAQ:GNTAIkena OncologyNASDAQ:IKNAPassage BioNASDAQ:PASGSemper Paratus AcquisitionNASDAQ:LGSTView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 14,157 shares on 3/11/2024Ownership: 0.610%Vanguard Group Inc.Bought 14,157 shares on 2/15/2024Ownership: 0.610%Citadel Advisors LLCBought 5,100 shares on 2/15/2024Ownership: 0.000%Northern Trust CorpBought 13,897 shares on 2/13/2024Ownership: 0.331%Aristides Capital LLCSold 9,800 shares on 2/13/2024Ownership: 0.087%View All Insider TransactionsView All Institutional Transactions CSBR Stock Analysis - Frequently Asked Questions Should I buy or sell Champions Oncology stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Champions Oncology in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CSBR shares. View CSBR analyst ratings or view top-rated stocks. What is Champions Oncology's stock price target for 2024? 2 brokers have issued twelve-month target prices for Champions Oncology's shares. Their CSBR share price targets range from $7.50 to $7.50. On average, they predict the company's stock price to reach $7.50 in the next twelve months. This suggests a possible upside of 53.1% from the stock's current price. View analysts price targets for CSBR or view top-rated stocks among Wall Street analysts. When is Champions Oncology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, July 22nd 2024. View our CSBR earnings forecast. How were Champions Oncology's earnings last quarter? Champions Oncology, Inc. (NASDAQ:CSBR) issued its earnings results on Tuesday, December, 12th. The biotechnology company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.02. The biotechnology company earned $11.57 million during the quarter, compared to analyst estimates of $12.62 million. Champions Oncology had a negative trailing twelve-month return on equity of 850.72% and a negative net margin of 19.76%. What is Ronnie Morris' approval rating as Champions Oncology's CEO? 8 employees have rated Champions Oncology Chief Executive Officer Ronnie Morris on Glassdoor.com. Ronnie Morris has an approval rating of 50% among the company's employees. This puts Ronnie Morris in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Champions Oncology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Champions Oncology investors own include Gilead Sciences (GILD), Intel (INTC), Cytosorbents (CTSO), Micron Technology (MU), Corbus Pharmaceuticals (CRBP), NVIDIA (NVDA), AbbVie (ABBV), Agile Therapeutics (AGRX), CRISPR Therapeutics (CRSP) and Exelixis (EXEL). Who are Champions Oncology's major shareholders? Champions Oncology's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (0.61%), Vanguard Group Inc. (0.61%), Essex Investment Management Co. LLC (0.57%), Northern Trust Corp (0.33%), Dimensional Fund Advisors LP (0.20%) and Aristides Capital LLC (0.09%). Insiders that own company stock include Daniel Newman Mendelson and Ronnie Morris. View institutional ownership trends. This page (NASDAQ:CSBR) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyFed launches fourth dollar overhaulStansberry ResearchMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Champions Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.